Svenska

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

MOVIE
Immunovia and
IMMray™ technology
(10 min)


Financial reports

February 2020

Immunovia AB published the company’s Full Year Report 2019 on Friday, February 14, 2020, at 8.00 a.m. CET.

Financial reports

Calendar

19-22 February, 2020
Deutscher Krebskongress 2020, German Cancer Congress
Place: Berlin, Germany
3-4 March, 2020
Carnegie Nordic Healthcare Seminar
Place: Stockholm, Sweden
30 March, 2020
PCUK Annual summit: Accelerating Success
Place: London, UK
All events
Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports